DGAP-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Quarter Results
The results for the first quarter of 2022, published today, reflect outstanding performance across all segments. Both group revenues and adjusted EBITDA in Q1 show double-digit growth and the organic growth rate remains in line with the mid-term ambitions of more than 5% by 2025. The share of recurring revenues reached 71% and reflects the high quality of revenues.
“We are very proud of the performance the team delivered in the first quarter and are seeing strong growth in all of our segments. CGM is driving digitization in healthcare. On our multi-year path of accelerated growth, the first quarter of 2022 represents yet another milestone”, Dr. Dirk Wössner, CEO of CompuGroup Medical, said, commenting the results.
Group: Revenues and adjusted EBITDA grow double-digit
Group revenues amounted to EUR 252 million, a growth of 10% (previous year: EUR 229 million). Organic revenue growth, adjusted for consolidation and currency effects, also stands strong at 5,4%.
Adjusted EBITDA reached EUR 52 million, which corresponds to a growth of 11% compared to the first quarter of 2021 and an adjusted EBITDA margin of 20.5% (previous year: 20.3%). During the first quarter of 2022 the quality of revenues, reflected by the share of recurring revenues, reached 71%.
CGM overall generated a consolidated profit of EUR 18.2 million in the first quarter (previous year: EUR 11 million). Adjusted earnings per share (diluted) amounted to EUR 0.41 (previous year: EUR 0.33), while free cashflow recorded slightly below last year’s level at EUR 65 million (previous year: EUR 70 million), in line with expectations.
"The continued strength of our diversified product portfolio delivered a strong quarterly performance and an excellent start into 2022“, says Chief Financial Officer (CFO) Michael Rauch. "We were able to add scope and traffic, further strengthening our excellent market position throughout Europe. With strong organic growth, supported by acquisitions, CGM is fully in line with our mid-term ambitions."
Excellent performance across all segments
Revenues in the Ambulatory Information Systems segment rose by 7% to EUR 120 million (previous year: EUR 112 million). The strong momentum in the digitization of healthcare systems constitutes the framework for this increase, which was further supported by currency and consolidation effects from last year’s acquisitions. Organically, revenues grew by 3%. This growth was mainly driven by a strong performance in the DACH region, especially in the dental sector as well as growth in the US. Recurring revenues amounted to 78% of total revenues, reflecting a growth of 8% year-on-year.
Another strong quarter has been recorded by the Hospital Information Systems segment, where revenues increased by 21% to EUR 67 million (previous year: EUR 55 million). This strong revenue growth was supported by the ongoing demand for innovative technologies that include the G3 platform and consolidation effects due to acquisitions. Organic growth stood at 9% in the first quarter of 2022. The share of recurring revenues increased to 70% compared to 68% in the first quarter of 2021.
The Consumer & Health Management Information Systems segment recorded revenues of EUR 35 million, after EUR 34 million in the first quarter 2021, which reflects an increase of 5% over the previous year. Due to excellent performance in the data business the organic growth rate in the CHS segment showed an increase of 14%, excluding TI. Recurring revenues rose by 16%, improving mainly due to the increasing TI-installed base, resulting in a share of recurring revenues of 47%.
The Pharmacy Information Systems segment recorded a positive revenue growth of 7% to EUR 30 million (previous year: EUR 28 million) mainly driven by the next generation EU tailwind for digitization initiatives in Italy. A strong performance in Germany has also had a positive influence on the results. Organic growth of 7% was in line with revenue development. The share of recurring revenues has shown a stable development and stands at 70%.
Contact for Media Representatives:
Contact for Analysts and Investors:
05.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||CompuGroup Medical SE & Co. KGaA|
|Maria Trost 21|
|Phone:||+49 (0)160 3630362|
|Fax:||+49 (0)261 8000 3200|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1344107|
|End of News||DGAP News Service|